In 2019,Photodermatology, Photoimmunology & Photomedicine included an article by Nicklas, Claudia; Rubio, Rocio; Cardenas, Consuelo; Hasson, Ariel. Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid. The article was titled 《Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris-A simple, blind, randomized, and controlled trial》. The information in the text is summarized as follows:
Although progress has been made in the study of photodynamic therapy for acne, studies using current recommended therapies as active comparators are lacking. Randomized, controlled trial involving 46 patients with moderate inflammatory facial acne, 23 patients received two sessions of PDT separated by 2 wk (ALA 20% incubated 1.5 h before red light irradiation with 37 J/cm2 fluence) and 23 patients received doxycycline 100 mg/d plus adapalene gel 0.1%. In both groups, from the sixth week, we started adapalene gel 0.1% as maintenance therapy until 12 wk of follow-up. Primary end point was the reduction of acne lesions at the 6-wk follow-up, which was evaluated by 2 investigators blinded to the intervention. The median percent reductions in noninflammatory lesion count (P = 0.013) and total lesions (P = 0.038) at 6 wk was found to be significantly higher in the group receiving PDT. At 12 wk there was a greater reduction of inflammatory lesions in PDT group with 84% vs. 74% for group who received doxycycline plus adapalene (P = 0.020) as well as in reducing total lesions with 79% vs. 67% resp. (P = 0.026). No severe side-effects were observed for either therapy. ALA-PDT offers promise as an alternative treatment for moderately severe inflammatory acne that has a higher effectiveness than the combination of doxycycline and adapalene gel in reducing noninflammatory and total lesions at 6 wk. There were significantly superior reductions at 12 wk in the combination of PDT group followed by adapalene gel in total, inflammatory, and noninflammatory lesions.6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas: 106685-40-9Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid) was used in this study.
6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid(cas:106685-40-9) may be used as a pharmaceutical reference standard for the quantification of the analyte in topical gel formulations using high-performance liquid chromatography technique.Safety of 6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem